HCV E2
Reaktivität: Hepatitis C Virus (HCV)
WB, EIA, IFA
Wirt: Maus
Monoclonal
unconjugated
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
4-5 mg/ml (OD280nm, E^0.1% = 1.4)
Buffer
0.01M PBS, pH 7.2
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C
Target
HCV E2
(Hepatitis C Virus Envelope Protein E2 (HCV E2))
Substanzklasse
Viral Protein
Hintergrund
Uev1A, also designated Uev1, UBE2V1 (for ubiquitin-conjugating enzyme E2 variant 1) and CROC1, shows sequence similarity to other ubiquitin-conjugating enzymes, but lacks the conserved cysteine residue critical for their catalytic activity. Therefore, Uev1A does not have ubiquitin-conjugating activity in vitro. However, constitutive expression of exogenous Uev1A in colon carcinoma cells inhibits their capacity to differentiate upon confluence. Studies on recombinant Uev1A show that it localizes to the nucleus, excluding the nucleolar regions. Uev1A functions with TRAF6, a RING domain protein, to catalyze the synthesis of unique polyubiquitin chains linked through Lysine 63 of ubiquitin. The gene encoding Uev1A maps to human chromosome 20q13.2.